Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Masimo Corporation
  6. Summary
    MASI   US5747951003

MASIMO CORPORATION

(MASI)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/21/2022 01/24/2022 01/25/2022 01/26/2022 01/27/2022 Date
217.91(c) 223.51(c) 212.98(c) 205.44(c) 199.49 Last
279 831 498 381 498 288 736 898 971 696 Volume
-1.69% +2.57% -4.71% -3.54% -2.90% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 1 233 M - -
Net income 2021 224 M - -
Net cash position 2021 762 M - -
P/E ratio 2021 52,9x
Yield 2021 -
Sales 2022 1 344 M - -
Net income 2022 252 M - -
Net cash position 2022 1 135 M - -
P/E ratio 2022 47,5x
Yield 2022 -
Capitalization 11 345 M 11 345 M -
EV / Sales 2021 8,58x
EV / Sales 2022 7,60x
Nbr of Employees 2 000
Free-Float 70,7%
More Financials
Company
Masimo Corporation is a global medical technology company that develops, manufactures, and markets noninvasive technologies and hospital automation solutions. Its patient monitoring solution that incorporates a monitor or circuit board, single-patient use or reusable sensors, software and cables. The CompanyÔÇÖs main products include Masimo Signal Extraction Technology (SET) pulse oximetry. Its product offerings... 
More about the company
Ratings of Masimo Corporation
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
C+
More Ratings
All news about MASIMO CORPORATION
01/17Retrospective Study Finds That Masimo SET« Pulse Oximetry Has No Difference in Accuracy..
BU
01/14MASIMO : SECOND AMENDMENT TO THE NOVEMBER 4, 2015 AMENDED AND RESTATED EMPLOYMENT AGREEMEN..
PU
01/14MASIMO CORP : Change in Directors or Principal Officers (form 8-K)
AQ
01/12INSIDER SELL : Masimo
MT
01/11Masimo Issues Guidance for 2022, Reports Preliminary Results for 2021
MT
01/11Masimo Announces Select Preliminary Full-Year 2021 Financial Results and 2022 Guidance
BU
01/11MASIMO : Announces Select Preliminary Full-Year 2021 Financial Results and 2022 Guidance -..
PU
01/11MASIMO CORP : Results of Operations and Financial Condition (form 8-K)
AQ
01/11Masimo Corporation Provides Earnings Guidance for the Years 2021 and 2022
CI
2021MASIMO : Q3 2021 Supplemental Presentation to Earnings Press Release
PU
2021Berenberg Bank Terminates Coverage on a Number of Companies Due to Analysts' Departures..
MT
2021New Study Suggests That Masimo SedLine« Brain Function Monitoring May Aid Early Identif..
BU
2021New Study Suggests That Masimo SedLine Brain Function Monitoring May Aid Early Identifi..
CI
2021INSIDER SELL : Masimo
MT
2021Masimo Rad-G« Helps Clinicians Identify Pediatric Pneumonia in Large Field Trial in Ind..
BU
More news
News in other languages on MASIMO CORPORATION
01/11Masimo publie des orientations pour 2022 et présente des résultats préliminaires pour 2..
01/11Masimo Corporation fournit des prévisions de résultats pour les années 2021 et 2022
2021Neue Studie legt nahe, dass die Überwachung der Gehirnfunktion mit Masimo SedLine« die ..
2021Une nouvelle étude suggère que la surveillance de la fonction cérébrale par SedLine« de..
2021Un nuevo estudio sugiere que el Monitoreo de la Función Cerebral SedLine« de Masimo pue..
More news
Analyst Recommendations on MASIMO CORPORATION
More recommendations
Chart MASIMO CORPORATION
Duration : Period :
Masimo Corporation Technical Analysis Chart | MASI | US5747951003 | MarketScreener
Technical analysis trends MASIMO CORPORATION
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 205,44 $
Average target price 298,20 $
Spread / Average Target 45,2%
EPS Revisions
Managers and Directors
Joe E. Kiani Chairman & Chief Executive Officer
Micah Young Chief Financial Officer & Executive Vice President
Yongsam Lee Chief Information Officer & Executive VP
Anand Sampath Executive VP-Operations & Clinical Research
Jon Curtis Coleman President-Worldwide Sales & Medical Affairs
Sector and Competitors
1st jan.Capi. (M$)
MASIMO CORPORATION-27.26%11 345
GETINGE AB-15.01%9 869
PENUMBRA, INC.-27.16%7 819
NOVOCURE LIMITED-16.10%6 540
ASAHI INTECC CO., LTD.-18.78%4 768
JIANGSU YUYUE MEDICAL EQUIPMENT & SUPPLY CO., LTD.-21.01%4 762